Scarica l'app Stockscreener
10.14
0.10%
0.010
Pre-mercato:
10.15
0.010
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$10.13
Aprire:
$10.12
Volume 24 ore:
6.55M
Relative Volume:
0.70
Capitalizzazione di mercato:
$11.82B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-3.1987
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+2.42%
1M Prestazione:
-3.43%
6M Prestazione:
+33.25%
1 anno Prestazione:
-10.50%
Intervallo 1D:
$10.06
$10.26
Intervallo di 1 settimana:
$9.92
$10.38
Portata 52W:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Confronta VTRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.14 | 11.81B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
142.77 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.82 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
456.84 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris shares break six-session winning streak - MSN
What analysts say about Viatris Inc stockRSI Overbought/Oversold & Small Entry Cost Trading - earlytimes.in
Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 - BioSpace
The Importance of a Global, Resilient Supply Chain to Access - CSRwire
Relative strength of Viatris Inc. in sector analysisProduct Launch & Reliable Price Action Trade Plans - newser.com
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Pharmaceutical Giant Viatris Schedules Q3 2025 Financial Results and Investor Conference Call for November 6 - Stock Titan
Will Viatris Inc. stock continue dividend increasesMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a Potential 20% Upside Amid High Dividend Yield - DirectorsTalk Interviews
Quantitative breakdown of Viatris Inc. recent moveJuly 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVTRS - 2822news.com
What drives Viatris Inc stock priceBear Market Strategies & Free Unstoppable Trading Performance - earlytimes.in
What drives Viatris Inc VIA stock priceStock Buyback Updates & Build Wealth With Expert Timing Advice - earlytimes.in
What analysts say about Viatris Inc VIA stockCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Viatris Inc VIA Stock Analysis and ForecastFederal Reserve Announcements & Explosive Profit Growth - Early Times
Is Viatris Stock Underperforming the Nasdaq? - MSN
Is Viatris Stock Underperforming The Nasdaq? - Barchart.com
Viatris: Indore Plant Could Boost 2026 Numbers (NASDAQ:VTRS) - Seeking Alpha
Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360
Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection - Insider Monkey
How Viatris’ (VTRS) Removal from the FTSE All-World Index Could Affect Investor Sentiment - Sahm
Viatris Inc.(NasdaqGS: VTRS) dropped from FTSE All-World Index - MarketScreener
Viatris (VTRS): Evaluating Valuation Following FDA Nod for Generic Iron Sucrose and Pipeline Progress - Sahm
Street Watch: Is Viatris Inc a defensive stock2025 Technical Patterns & Weekly Stock Performance Updates - خودرو بانک
Fundamentals Check: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com
Will Viatris Inc. see short term momentum2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Trading Recap: Can Viatris Inc. withstand a market correctionInsider Selling & Precise Trade Entry Recommendations - khodrobank.com
Forecast Cut: How do insiders feel about Viatris IncWeekly Stock Report & Long Hold Capital Preservation Tips - خودرو بانک
Short Covering: Will Viatris Inc stock hit new highs in YEAROil Prices & Free Verified High Yield Trade Plans - khodrobank.com
Viatris pulls generic for Teva’s Trisenox in EU - MSN
VIX Spike: Can Viatris Inc ride the EV waveRisk Management & Reliable Momentum Entry Alerts - خودرو بانک
Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light - MSN
Viatris (VTRS) Recovers Slightly But Struggles Amid Market Conce - GuruFocus
Viatris rises after a steep seven-day slide - MSN
Day 7 of Loss Streak for Viatris Stock with -9% Return (vs. -20% YTD) [9/16/2025] - Trefis
Institution Moves: Can Viatris Inc ride the EV waveLong Setup & Daily Momentum Trading Reports - خودرو بانک
Volatility Watch: Is Viatris Inc stock suitable for long term investing2025 Bull vs Bear & Weekly High Conviction Trade Ideas - خودرو بانک
Market Moves: Is now the right time to enter Viatris IncJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - khodrobank.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Aug Swings: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com
Market Leaders: Can Viatris Inc. navigate macro headwindsQuarterly Profit Report & Consistent Return Strategy Ideas - خودرو بانک
Viatris chief commercial officer Le Goff sells $72k in stock - Investing.com Nigeria
Viatris chief commercial officer Le Goff sells $72k in stock By Investing.com - Investing.com South Africa
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.43%
5.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):